Skip to main content
placeholder image

Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breat Cancer Metastasis

Chapter


Abstract


  • Breast cancer is the most common malignancy afflicting Western

    women today and causes many deaths due to metastatic disease. Upregulation of

    the plasminogen-activation system (PAS) strongly correlates with poor prognosis

    in metastatic breast cancer and targeting this system is a promising strategy for

    developing prophylactic anti-metastasis drugs. Two classes of PAS-targeting

    agents are inhibitors of the serine protease activity of urokinase plasminogen

    activator (uPA) and antagonists of the interaction of uPA with its cell surface

    receptor (uPAR). This review provides an overview of the role of PAS in cancer

    metastasis before discussing the small molecules and peptides from the patent

    literature since 2000 that target either uPA or uPA/uPAR interactions for use as

    anti-metastasis drugs

Publication Date


  • 2010

Citation


  • Tyndall, J. D. A.., Kelso, M. J. & Ranson, M. (2010). Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breat Cancer Metastasis. In D. Atta-ur-Rahman & D. Iqbal Choudhary (Eds.), Frontiers in Anti-Cancer Drug Discovery (pp. 55-78). online: Bentham Science Publishers Ltd.

Ro Metadata Url


  • http://ro.uow.edu.au/scipapers/5193

Book Title


  • Frontiers in Anti-Cancer Drug Discovery

Start Page


  • 55

End Page


  • 78

Abstract


  • Breast cancer is the most common malignancy afflicting Western

    women today and causes many deaths due to metastatic disease. Upregulation of

    the plasminogen-activation system (PAS) strongly correlates with poor prognosis

    in metastatic breast cancer and targeting this system is a promising strategy for

    developing prophylactic anti-metastasis drugs. Two classes of PAS-targeting

    agents are inhibitors of the serine protease activity of urokinase plasminogen

    activator (uPA) and antagonists of the interaction of uPA with its cell surface

    receptor (uPAR). This review provides an overview of the role of PAS in cancer

    metastasis before discussing the small molecules and peptides from the patent

    literature since 2000 that target either uPA or uPA/uPAR interactions for use as

    anti-metastasis drugs

Publication Date


  • 2010

Citation


  • Tyndall, J. D. A.., Kelso, M. J. & Ranson, M. (2010). Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breat Cancer Metastasis. In D. Atta-ur-Rahman & D. Iqbal Choudhary (Eds.), Frontiers in Anti-Cancer Drug Discovery (pp. 55-78). online: Bentham Science Publishers Ltd.

Ro Metadata Url


  • http://ro.uow.edu.au/scipapers/5193

Book Title


  • Frontiers in Anti-Cancer Drug Discovery

Start Page


  • 55

End Page


  • 78